CONCLUSIONS

Paediatric sarcomas are heterogeneous group of disorders and nearly one-third of them presents with metastasis at presentation and another one-third relapsed after initial curative therapies. Not much of therapeutic developments happened in relapsed/refractory paediatric sarcomas and current treatment options are very much limited in terms of cure or long-term control. Multimodality treatment with chemotherapy, surgery and/or radiotherapy can be curative options in some limited relapsed cases or when relapse occurs after a long remission. But, in the majority of remaining cases, treatment refractoriness remains the main challenge and possesses a huge unmet need. Current newer strategies including targeted therapies, salvage chemotherapy, ASCT, immunotherapeutic approach, adoptive cellular therapies only produced modest & temporary responses, so far. Better understanding of disease biology, mechanism of treatment refractoriness, well-designed clinical trials, combination chemo-immunotherapeutic strategy, better national and international collaboration, translational research remains the key to success and fulfils the unmet need.

Disclosure


Continue Reading

The authors report no conflicts of interest in this work.

References

1. Biswas B, Rastogi S, Khan SA, et al. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing’s sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clin Oncol. 2014;26(11):722–729. doi:10.1016/j.clon.2014.05.006

2. Iqbal N, Shukla NK, Deo SVS, et al. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients. Clin Transl Oncol. 2016;18(3):310–316. doi:10.1007/s12094-015-1369-9

3. Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016;47(1):283–292. doi:10.1016/j.ocl.2015.08.022

4. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011;47(6):895–902.

5. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–3046. doi:10.1200/JCO.2014.59.5256

6. Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57(4):549–553. doi:10.1002/pbc.23040

7. Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat Rev Dis Primer. 2018;4:1.

8. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study Group. J Clin Oncol. 1999;17(11):3487–3493. doi:10.1200/JCO.1999.17.11.3487

9. Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol. 2008;26(3):406–413. doi:10.1200/JCO.2007.12.2382

10. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol. 2011;29(10):1319–1325. doi:10.1200/JCO.2010.32.1984

11. Sung L, Anderson JR, Donaldson SS, et al. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Eur J CanceR. 1990. 2004;40(12):1878–1885.

12. Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005;104(1):183–190. doi:10.1002/cncr.21138

13. Dasgupta R, Rodeberg D. Non-rhabdomyosarcoma. Semin Pediatr Surg. 2016;25(5):284–289. doi:10.1053/j.sempedsurg.2016.09.012

14. Parida L, Fernandez-Pineda I, Uffman JK, et al. Clinical management of infantile fibrosarcoma: a retrospective single-institution review. Pediatr Surg Int. 2013;29(7):703–708. doi:10.1007/s00383-013-3326-4

15. Loh ML, Ahn P, Perez-Atayde AR, Gebhardt MC, Shamberger RC, Grier HE. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. J Pediatr Hematol Oncol. 2002;24(9):722–726.

16. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7(11):967–976. doi:10.1593/neo.05394

17. Tirino V, Desiderio V, d’Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One. 2008;3(10):e3469.

18. Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010;70(11):4602–4612. doi:10.1158/0008-5472.CAN-09-3463

19. Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling. Cancer Lett. 2016;370(2):286–295. doi:10.1016/j.canlet.2015.11.013

20. Tang Q-L, Liang Y, Xie X-B, et al. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer. 2011;30(6):426–432. doi:10.5732/cjc.011.10127

21. Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189–195. doi:10.1016/j.canlet.2016.11.019

22. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis. 2003;20(6):525–529. doi:10.1023/A:1025821229013

23. Zhang F, Chen A, Chen J, Yu T, Guo F. siRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells. Asian Pac J Cancer. 2011;12(1):239–245.

24. Wu J, Liao Q, He H, Zhong D, Yin K. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog. 2014;53(6):440–446. doi:10.1002/mc.21991

25. Ma Y, Ren Y, Han EQ, et al. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013;431(2):274–279. doi:10.1016/j.bbrc.2012.12.118

26. Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. Cancer Lett. 2013;338(1):158–167. doi:10.1016/j.canlet.2012.05.028

27. Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs. 2008;19(3):257–265. doi:10.1097/CAD.0b013e3282f435b6

28. Baldini N, Scotlandi K, Barbanti-Bròdano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333(21):1380–1385. doi:10.1056/NEJM199511233332103

29. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012;118(7):1856–1867. doi:10.1002/cncr.26472

30. Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer. 2003;98(9):1958–1966. doi:10.1002/cncr.11741

31. Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr. 2009;154(5):688–693. doi:10.1016/j.jpeds.2008.11.030

32. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase π, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Cancer. 1997;79(12):2336–2344. doi:10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J

33. Wei L, Song X-R, Wang X-W, Li M, Zuo W-S. Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance. Zhonghua Zhong Liu Za Zhi. 2006;28(6):445–448.

34. Biason P, Hattinger CM, Innocenti F, et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J. 2012;Dec;12(6):476–483. doi:10.1038/tpj.2011.33

35. Caronia D, Patiño-García A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009;9(5):347–353. doi:10.1038/tpj.2009.19

36. Li J, Liu S, Wang W, et al. ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol. 2014;35(10):10129–10136. doi:10.1007/s13277-014-2322-1

37. Yang J, Yang D, Cogdell D, et al. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat. 2010;9(2):161–169. doi:10.1177/153303461000900205

38. Chen R, Wang G, Zheng Y, Hua Y, Cai Z. Drug resistance‐related microRNAs in osteosarcoma: translating basic evidence into therapeutic strategies. J Cell Mol Med. 2019;23(4):2280–2292. doi:10.1111/jcmm.14064

39. Lin PP, Wang Y, Lozano G. Mesenchymal stem cells and the origin of Ewing’s sarcoma. Sarcoma. 2011;2011.

40. Ahmed AA, Zia H, Wagner L. Therapy resistance mechanisms in Ewing’s sarcoma family tumors. Cancer Chemother Pharmacol. 2014;73(4):657–663. doi:10.1007/s00280-014-2392-1

41. Scotlandi K, Remondini D, Castellani G, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol. 2009;27(13):2209–2216. doi:10.1200/JCO.2008.19.2542

42. Mendoza-Naranjo A, El-Naggar A, Wai DH, et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013;5(7):1087–1102. doi:10.1002/emmm.201202343

43. Crompton BD, Stewart C, Taylor-Weiner A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326–1341. doi:10.1158/2159-8290.CD-13-1037

44. Wu X, Xiao H, Wang R, Liu L, Li C, Lin J. Persistent GP130/STAT3 signaling contributes to the resistance of doxorubicin, cisplatin, and MEK inhibitor in human rhabdomyosarcoma cells. Curr Cancer Drug Targets. 2016;16(7):631–638. doi:10.2174/1568009615666150916093110

45. Citti A, Boldrini R, Inserra A, et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. Int J Oncol. 2012;41(1):117–124. doi:10.3892/ijo.2012.1433

46. Schmid E, Stagno MJ, Yan J, et al. Serum and glucocorticoid inducible kinase 1-sensitive survival, proliferation and migration of rhabdomyosarcoma cells. Cell Physiol Biochem. 2017;43(3):1301–1308. doi:10.1159/000481842

47. Seitz G, Bonin M, Fuchs J, et al. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. Int J Oncol. 2010;36(2):491–500.

48. Bhuvaneshwar K, Harris M, Gusev Y, et al. Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients. BMC Cancer. 2019;19:1. doi:10.1186/s12885-019-5474-y

49. Chiappetta C, Mancini M, Lessi F, et al. Whole-exome analysis in osteosarcoma to identify a personalized therapy. Oncotarget. 2017;8:46. doi:10.18632/oncotarget.19010

50. Subbiah V, Wagner MJ, McGuire MF, et al. Personalized comprehensive molecular profiling of high risk osteosarcoma: implications and limitations for precision medicine. Oncotarget. 2015;6(38):38. doi:10.18632/oncotarget.5841

51. Chang W, Brohl AS, Patidar R, et al. MultiDimensional clinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research. Clin Cancer Res. 2016;22(15):3810–3820. doi:10.1158/1078-0432.CCR-15-2717

52. Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study. Eur J Cancer. 2016;65:91–101. doi:10.1016/j.ejca.2016.06.009

53. Khater F, Vairy S, Langlois S, et al. Molecular profiling of hard-to-treat childhood and adolescent cancers. JAMA Netw Open. 2019;2(4):e192906. doi:10.1001/jamanetworkopen.2019.2906

54. Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017;8:24. doi:10.18632/oncotarget.16845

55. Weidenbusch B, Richter GHS, Kesper MS, et al. Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. Oncotarget. 2018;9(29):29. doi:10.18632/oncotarget.25087

56. Suehara Y, Alex D, Bowman A, et al. Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin Cancer Res. 2019;25(21):6346–6356. doi:10.1158/1078-0432.CCR-18-4032

57. Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011;117(21):4925–4938. doi:10.1002/cncr.26116

58. Hayes-Jordan A, Doherty DK, West SD, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg. 2006;41(4):633–638. doi:10.1016/j.jpedsurg.2005.12.002

59. De Corti F, Bisogno G, Dall’Igna P, et al. Does surgery have a role in the treatment of local relapses of non-metastatic rhabdomyosarcoma? Pediatr Blood Cancer. 2011;57(7):1261–1265. doi:10.1002/pbc.23225

60. Angelini L, Bisogno G, Alaggio R, et al. Prognostic factors in children undergoing salvage surgery for bladder/prostate rhabdomyosarcoma. J Pediatr Urol. 2016;12(4):265.e1–8. doi:10.1016/j.jpurol.2016.04.014

61. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol. 1995;17(3):265–269. doi:10.1097/00043426-199508000-00009

62. Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44(4):338–347. doi:10.1002/pbc.20227

63. Rl S, Kc S, J S J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group Phase II Study. J Clin Oncol. 2001.

64. Compostella A, Affinita MC, Casanova M, et al. Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: report from the AIEOP Soft Tissue Sarcoma Committee. Tumori. 2019;105(2):138–143. doi:10.1177/0300891618792479

65. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28(30):4658–4663. doi:10.1200/JCO.2010.29.7390

66. Abstracts S. Pediatr blood cancer. 2019;66(S4):e27989.

67. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001;23(5):272–276. doi:10.1097/00043426-200106000-00007

68. Peinemann F, Kröger N, Bartel C, et al. High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma–a systematic review. PLoS One. 2011;6(2):e17127. doi:10.1371/journal.pone.0017127

69. Rengaswamy V, Zimmer D, Süss R, Rössler J. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. J Controlled Release. 2016;235:319–327. doi:10.1016/j.jconrel.2016.05.063

70. Gryder BE, Yohe ME, Chou H-C, et al. PAX3–FOXO1 establishes myogenic super enhancers and confers bet bromodomain vulnerability. Cancer Discov. 2017;7(8):884–899. doi:10.1158/2159-8290.CD-16-1297

71. Böhm M, Wachtel M, Marques JG, et al. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. J Clin Invest. 2016;126(11):4237–4249. doi:10.1172/JCI85057

72. Chen C, Dorado Garcia H, Scheer M, Henssen AG. Current and future treatment strategies for rhabdomyosarcoma. Front Oncol. 2019;20;9(20):1903–1904. doi:10.1016/0006-2952(75)90415-3

73. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341(5):342–352. doi:10.1056/NEJM199907293410507

74. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–1606. doi:10.1056/NEJM198606193142502

75. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011;47(6):895–902.

76. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–568. doi:10.1200/JCO.2005.04.063

77. Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol. 2006;28(7):418–422. doi:10.1097/01.mph.0000212944.82361.1d

78. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007;96(2):118–123. doi:10.1002/jso.20628

79. Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br. 2002;84(1):88–92.

80. Grimer RJ, Sommerville S, Warnock D, et al. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer. 2005;41(4):578–583. doi:10.1016/j.ejca.2004.11.012

81. Nathan SS, Gorlick R, Bukata S, et al. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer. 2006;107(7):1607–1616. doi:10.1002/cncr.22197

82. Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol Stockh Swed. 2005;44(7):748–755. doi:10.1080/02841860500327503

83. Palmerini E, Torricelli E, Cascinu S, et al. Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? Pediatr Blood Cancer. 2019;66(8):e27792. doi:10.1002/pbc.27792

84. Harting MT, Blakely ML. Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg. 2006;15(1):25–29. doi:10.1053/j.sempedsurg.2005.11.005

85. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the memorial sloan-kettering cancer center experience. Cancer. 2005;104(10):2214–2221. doi:10.1002/cncr.21417

86. Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.. J Clin Oncol. 1994;12(12):2614–2620. doi:10.1200/JCO.1994.12.12.2614

87. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–565. doi:10.1200/JCO.2008.16.2305

88. Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A, Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol. 2010;19(4):193–199. doi:10.1016/j.suronc.2009.05.002

89. Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer. 2003;39(14):2050–2057. doi:10.1016/S0959-8049(03)00435-0

90. Hawkins DS, Arndt CAS. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98(11):2447–2456. doi:10.1002/cncr.11799

91. de Baere T, Tselikas L, Gravel G, et al. Interventional radiology: role in the treatment of sarcomas. Eur J Cance. 2018;94:148–155. doi:10.1016/j.ejca.2018.02.017

92. Yu W, Liu Z, Tang L, Lin F, Yao Y, Shen Z. Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: experience in 73 patients. Sci Rep. 2017;7(1):17480. doi:10.1038/s41598-017-14521-7

93. Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. Acta Orthop. 2006;77(6):938–943. doi:10.1080/17453670610013268

94. Franke M, Hardes J, Helmke K, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 2011;56(5):771–776.

95. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20(1):189–196. doi:10.1200/JCO.2002.20.1.189

96. Loeb DM, Garrett-Mayer E, Hobbs RF, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009;115(11):2514–2522. doi:10.1002/cncr.24286

97. Subbiah V, Anderson P, Rohren E. Alpha emitter radium 223 in high-risk osteosarcoma: first clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 2015;1(2):253–255. doi:10.1001/jamaoncol.2014.289

98. Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014;804:291–304.

99. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995;24(2):87–92. doi:10.1002/mpo.2950240205

100. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997;33(2):232–237.

101. Lee JA, Jeon D-G, Cho WH, et al. Higher gemcitabine dose was associated with better outcome of osteosarcoma patients receiving gemcitabine-docetaxel chemotherapy. Pediatr Blood Cancer. 2016;63(9):1552–1556. doi:10.1002/pbc.26058

102. Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012;17(3):321. doi:10.1634/theoncologist.2010-0265

103. Berger M, Massimo B, Grignani G, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 2009;115(13):2980–2987. doi:10.1002/cncr.24368

104. Rodríguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol. 2002;24(4):250–255. doi:10.1097/00043426-200205000-00006

105. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508–516. doi:10.1093/annonc/mdr151

106. Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107. doi:10.1016/S1470-2045(14)71136-2

107. Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20(1):120–133. doi:10.1016/S1470-2045(18)30742-3

108. Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37(16):1424–1431. doi:10.1200/JCO.18.02374

109. Lashkari A, Chow WA, Valdes F, et al. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res. 2009;29(8):3281–3288.

110. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol. 2002;20(8):2150–2156.

111. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. doi:10.1016/S1470-2045(17)30624-1

112. Arndt CAS, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children’s Oncology Group. Clin Cancer Res. 2010;16(15):4024–4030.

113. US Department of Health and Human Services; National Cancer Institute. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 19751995. American Psychological Association; 1999.

114. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(3):334–338. doi:10.1002/pbc.21618

115. Bacci G, Longhi A, Ferrari S, et al. Pattern of relapse in 290 patients with nonmetastatic Ewing’s sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol. 2006;32(9):974–979. doi:10.1016/j.ejso.2006.01.023

116. Wasilewski-Masker K, Liu Q, Yasui Y, et al. Late Recurrence in Pediatric Cancer: A Report From the Childhood Cancer Survivor Study. JNCI J Natl Cancer Inst. 2009;101(24):1709–1720. doi:10.1093/jnci/djp417

117. Heinemann M, Ranft A, Langer T, et al. Recurrence of Ewing sarcoma: is detection by imaging follow-up protocol associated with survival advantage? Pediatr Blood Cancer. 2018;65(7):e27011. doi:10.1002/pbc.27011

118. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer. 2002;94(2):561–569. doi:10.1002/cncr.10192

119. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132–139. doi:10.1002/pbc.20697

120. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463–3469. doi:10.1200/JCO.2001.19.15.3463

121. Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive Ewing sarcoma family tumors. Pediatr Hematol Oncol. 2013;30(3):170–177. doi:10.3109/08880018.2013.767868

122. Tanaka K, Joyama S, Chuman H, et al. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients. World J Surg Oncol. 2016;14:306. doi:10.1186/s12957-016-1059-2

123. Ferrari S, Del Prever AB, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009;52(5):581–584. doi:10.1002/pbc.21917

124. Palmerini E, Jones RL, Setola E, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol Stockh Swed. 2018;57(7):958–964. doi:10.1080/0284186X.2018.1449250

125. Devadas SK, Banavali S. Retrospective analysis of outcomes of patients with relapsed, refractory and metastatic sarcomas who have received metronomic chemotherapy. Gulf J Oncolog. 2019;1(30):22–28.

126. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep. 2009;11(4):307–313. doi:10.1007/s11912-009-0043-1

127. Richter GHS, Fasan A, Hauer K, et al. G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. J Pathol. 2013;230(1):70–81. doi:10.1002/path.4170

128. Attia S, Bolejack V, Ganjoo KN, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017;35(15_suppl):11005. doi:10.1200/JCO.2017.35.15_suppl.11005

129. Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collab … | oncologyPRO [Internet]. Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Cabozantinib-in-Patients-With-Advanced-Osteosarcomas-and-Ewing-sarcomas-a-French-Sarcoma-Group-FSG-US-National-Cancer-Institute-phase-II-collaborative-study. Accessed May 18, 2020.

130. van Maldegem AM, JVMG B, Peterse EFP, Hogendoorn PCW, Gelderblom H. Ewing sarcoma: the clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. Eur J Cancer. 2016;53:171–180. doi:10.1016/j.ejca.2015.09.009

131. Zöllner SK, Selvanathan SP, Graham GT, et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Sci Signal. 2017;10:499. doi:10.1126/scisignal.aam8429

132. Gollavilli PN, Pawar A, Wilder-Romans K, et al. EWS/ETS-driven Ewing sarcoma requires BET bromodomain proteins. Cancer Res. 2018;78(16):4760–4773. doi:10.1158/0008-5472.CAN-18-0484

133. Theisen ER, Pishas KI, Saund RS, Lessnick SL. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. 2016;7(14):17616–17630. doi:10.18632/oncotarget.7124

134. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29(34):4541–4547. doi:10.1200/JCO.2010.34.0000

135. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(3):256–262. doi:10.1200/JCO.2011.37.4355

136. Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012;30(15):1849–1856. doi:10.1200/JCO.2011.37.2359

137. Wagner LM, Fouladi M, Ahmed A, et al. Phase II Study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the children’s oncology group. Pediatr Blood Cancer. 2015;62(3):440–444. doi:10.1002/pbc.25334

138. Choy E, Butrynski JE, Harmon DC, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;5(14):813. doi:10.1186/1471-2407-14-813

139. Ghisoli M, Barve M, Schneider R, et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther. 2015;23(6):1103–1109. doi:10.1038/mt.2015.43

140. Gargallo P, Juan A, Yáñez Y, et al. Precision medicine in Ewing sarcoma: a translational point of view. Clin Transl Oncol. 2020. doi:10.1007/s12094-020-02298-7

141. Machado I, López-Guerrero JA, Scotlandi K, Picci P, Llombart-Bosch A. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT). Virchows Arch. 2018;472(5):815–824. doi:10.1007/s00428-018-2316-2

142. Van Mater D, Wagner L. Management of recurrent Ewing sarcoma: challenges and approaches. OncoTargets Ther. 2019;27(12):2279–2288. doi:10.2147/OTT.S170585

143. Rao DD, Jay C, Wang Z, et al. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing’s Sarcoma. Mol Ther. 2016;24(8):1412–1422. doi:10.1038/mt.2016.93

144. Ghisoli M, Barve M, Mennel R, et al. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in metastatic advanced ewing’s sarcoma. Mol Ther. 2016;24(8):1478–1483. doi:10.1038/mt.2016.86

145. Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014;61(8):1382–1386. doi:10.1002/pbc.25042

146. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol. 2005;23(19):4354–4362. doi:10.1200/JCO.2005.05.105

147. McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours. Ann Oncol. 2006;17(8):1301–1305. doi:10.1093/annonc/mdl108

148. Hayani A, Mahoney DH, Hawkins HK, Steuber CP, Hurwitz R, Fernbach DJ. Soft-tissue sarcomas other than rhabdomyosarcoma in children. Med Pediatr Oncol. 1992;20(2):114–118. doi:10.1002/mpo.2950200205

149. Orbach D, Rey A, Oberlin O, et al. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol. 2005;23(19):4363–4371.

150. Coffin CM, Dehner LP. Soft tissue tumors in first year of life: a report of 190 cases. Pediatr Pathol. 1990;10(4):509–526. doi:10.3109/15513819009067140

151. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184–187. doi:10.1038/ng0298-184

152. Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: management based on the European experience. J Clin Oncol. 2010;28(2):318–323. doi:10.1200/JCO.2009.21.9972

153. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448

154. André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–431. doi:10.1038/nrclinonc.2014.89

155. Porkholm M, Toiviainen-Salo S, Seuri R, et al. Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential. Acta Paediatr. 2016;105(8):946–951. doi:10.1111/apa.13338

156. André N, Abed S, Orbach D, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget. 2011;2(12):960–965. doi:10.18632/oncotarget.358

157. Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA. 2017;3(9):1222.

158. Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017.

159. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105

160. Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870. doi:10.1371/journal.pone.0082870

161. Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6):1364–1370. doi:10.1158/1078-0432.CCR-15-0491

162. Groisberg R, Hong DS, Behrang A, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5(1):100. doi:10.1186/s40425-017-0301-y

163. Davis KL, Fox E, Reid JM, et al. ADVL1412: initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. J Clin Oncol. 2017;35(15_suppl):10526. doi:10.1200/JCO.2017.35.15_suppl.10526

164. Merchant MS, Bernstein D, Amoako M, et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. 2016;22(13):3182–3191. doi:10.1158/1078-0432.CCR-15-2550

165. Folkert IW, Devalaraja S, Linette GP, Weber K, Haldar M. Primary bone tumors: challenges and opportunities for CAR‐T therapies. J Bone Miner Res. 2019;34(10):1780–1788. doi:10.1002/jbmr.3852

166. Zhu H, Gu S, Yin M, et al. Analysis of infantile fibrosarcoma reveals extensive T-cell responses within tumors: implications for immunotherapy. Pediatr Blood Cancer. 2018;65(2):e26813. doi:10.1002/pbc.26813

167. Chang T-C, Carter RA, Li Y, et al. The neoepitope landscape in pediatric cancers. Genome Med. 2017;9(1):78. doi:10.1186/s13073-017-0468-3

168. Pilbeam K, Wang H, Taras E, et al. Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. Oncotarget. 2017;9(15):11938–11947. doi:10.18632/oncotarget.21187

169. Sp D, Mr M, Ba VT, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, Phase 2 Trials. Lancet Oncol. 2018.

170. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005

171. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61(23):8513–8519.

172. Ahmed N, Brawley VS, Hegde M, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688–1696. doi:10.1200/JCO.2014.58.0225

173. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;13;379(24):2342–2350. doi:10.1056/NEJMoa1809697

174. Klingebiel T, Pertl U, Hess CF, et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol. 1998;30(5):269–275. doi:10.1002/(SICI)1096-911X(199805)30:5<269::AID-MPO2>3.0.CO;2-D

175. Defachelles AS, Bogart E, Casanova M, et al. Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS). J Clin Oncol. 2019;37(15_suppl):10000. doi:10.1200/JCO.2019.37.15_suppl.10000

176. Setty BA, Stanek JR, Mascarenhas L, et al. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. Pediatr Blood Cancer. 2018;65(1):e26728. doi:10.1002/pbc.26728

177. Kuttesch JF, Krailo MD, Madden T, Johansen M, Bleyer A. Children’s Oncology Group. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer. 2009;53(4):590–593. doi:10.1002/pbc.22133

178. Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer. 2002;94(12):3263–3268. doi:10.1002/cncr.10600

179. Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004;101(7):1664–1671. doi:10.1002/cncr.20544

180. Minard-Colin V, Ichante J-L, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma–a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer Oxf Engl 1990. 2012;48(15):2409–2416.

181. Mascarenhas L, Meyer WH, Lyden E, et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). J Clin Oncol. 2014;32(15_suppl):10003. doi:10.1200/jco.2014.32.15_suppl.10003

182. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012;59(5):854–858. doi:10.1002/pbc.24101

183. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993;71(5):1898–1903. doi:10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q

184. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol off J Am Soc Clin Oncol. 1987;5(8):1191–1198. doi:10.1200/JCO.1987.5.8.1191

185. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol. 2001;23(1):30–38. doi:10.1097/00043426-200101000-00008

186. Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer. 2005;44(3):215–219. doi:10.1002/pbc.20228

187. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419–425. doi:10.1002/cncr.23586

188. Qi W-X, He A-N, Tang L-N, Shen Z, Lin F, Yao Y. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol. 2012;42(5):427–431. doi:10.1093/jjco/hys030

189. Palmerini E, Jones RL, Marchesi E, et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 2016;16:280. doi:10.1186/s12885-016-2312-3

190. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008;17(11):1703–1715. doi:10.1517/13543784.17.11.1703

191. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009;53(6):1029–1034. doi:10.1002/pbc.22206

192. Hernández-Marqués C, Lassaletta-Atienza A, Ruiz Hernández A, et al. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors]. An Pediatr Barc Spain. 2013;79(2):68–74. Spanish.

193. Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013;60(10):1621–1625. doi:10.1002/pbc.24621

194. Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolomide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature. Pediatr Hematol Oncol. 2015;32(1):50–59. doi:10.3109/08880018.2014.954070

195. Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E, Çakır FB. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. J Oncol Pharm Pract off Publ Int Soc Oncol Pharm Pract. 2019;25(6):1343–1348. doi:10.1177/1078155218790798

196. Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006;47(6):795–800. doi:10.1002/pbc.20719

197. Farhat R, Raad R, Khoury NJ, et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013;35(5):356–360. doi:10.1097/MPH.0b013e318270a343

198. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009;31(10):723–729. doi:10.1097/MPH.0b013e3181b2598c

199. van Maldegem AM, Benson C, Rutkowski P, et al. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. Pediatr Blood Cancer. 2015;62(1):40–44. doi:10.1002/pbc.25230

Source: OncoTargets and Therapy.
Originally published June 8, 2020.

READ FULL ARTICLE Curated publisher From Dovepress